PubMed Health⌕ Search

Biomedical subjects

H M Cullis

Publications and source records attributed to H M Cullis.

3 recordsLinked to original sources

Peripheral blood CD34+ cells differ from bone marrow CD34+ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor.

Granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) have been shown to stimulate the circulation of hematopoietic progenitor cells in both mice and nonhuman primates. We evaluated the immunophenotype and cell cycle status of CD34+ cells isolated from the bone marrow (BM) and leukapheresis product of cytokine-mobilized nonhuman primates. CD34+ cells were isolated from rhesus macaques that had received no cytokine therapy, 100 micrograms/kg/d G-CSF, 200 micrograms/kg/d SCF, or a combination of both 100 micrograms/kg/d G-CSF and 200 micrograms/kg/d SCF as a subcutaneous injection for 5 days. BM was aspirated before (day 0) and on the last day (day 5) of cytokine administration. On days 4 and 5, peripheral blood (PB) mononuclear cells were collected using a novel method of leukapheresis. Threefold more PB mononuclear cells were collected from animals receiving G-CSF alone or G-CSF and SCF than from animals that had received either SCF alone or no cytokine therapy. CD34+ cells were positively selected using an immunoadsorptive system from the BM, PB, and/or leukapheresis product. Threefold and 10-fold more CD34+ cells were isolated from the leukapheresis product of animals receiving G-CSF or G-CSF and SCF, respectively, than from animals receiving no cytokine therapy or SCF alone. The isolated CD34+ cells were immunophenotyped using CD34-allophycocyanin, CD38-fluorescein isothiocyanate, and Thy-1-phycoerythrin. These cells were later stained with 4', 6-diamidino-2-phenylindole for simultaneous DNA analysis and immunophenotyping. BM-derived CD34+ cells did not differ significantly in cell cycle status and Thy-1 or CD38 phenotype before or after G-CSF and/or SCF administration. Similarly, CD34+ cells isolated from the leukapheresis product did not differ significantly in immunophenotype or cell cycle status before or after G-CSF and/or SCF administration. However, there were consistent differences in both immunophenotype and cell cycle status between BM- and PB-derived CD34+ cells. CD34+ cells isolated from the PB consistently had a smaller percentage of cells in the S+G2/M phase of the cell cycle and had a higher percentage of cells expressing Thy-1 than did CD34+ cells isolated from the BM. A greater proportion of PB-derived CD34+ cells were in the S+G2/M phase of the cell cycle after culture in media supplemented with interleukin-6 and SCF, However, culturing decreased the proportion of CD34+ cells expressing Thy-1.

ADP-ribosyl Cyclase↗

A technique to reduce lymphocyte contamination of plateletapheresis products collected with a centrifugal blood cell separator.

It is desirable to minimize the contamination of plateletapheresis products by lymphocytes because of the role these cells may play in febrile nonhemolytic transfusion reactions, alloimmunization, platelet deterioration during storage and also to reduce donor lymphocyte loss. This study attempted to determine whether lymphocyte contamination could be reduced by rapidly depleting plasma from the separation chamber at selected intervals during plateletapheresis with a blood cell separator (CS-3000, Fenwal). Donors who provided platelet components with more than 0.10 X 10(9) lymphocytes without rapid depletion underwent a second plateletapheresis procedure in which the rapid depletion technique was used. The plasma pump was reprogrammed to remove rapidly 12 ml of plasma from the separation chamber (pump speed 48 ml/min) immediately after the plasma pump reversal. All other collection techniques were identical for all procedures. Significantly fewer lymphocytes were collected in those procedures in which rapid depletion was used (mean, 0.187 X 10(9] than when it was not used (mean, 0.331 X 10(9] (p = 0.001, n = 30). There was no effect on platelet yield, efficiency of platelet collection, processing time, or total collection time. This procedure provides a product that should be considered for routine use.

Blood Component Removal↗